Armata Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $54.9M
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on bacteriophage-based therapies. As of November 6, 2026, the company had 37,192,632 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
- Key figure
- Net income $54.9M